Who We Are
Leadership
Milestone
Awards
Contact
About Mabwell

Mabwell (SSE: 688062) is an innovation-driven biopharmaceutical company, has the entire industry chain of R&D, manufacturing, and commercialization. We are committed to provide more effective and accessible therapy and innovative medicines to fulfill global medical needs.
Innovation-driven Biopharmaceutical Company with Entire Industry Chain Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established.
Innovative Pipeline Advancing Across Diverse Area Mabwell's robust pipeline currently comprises 15 high-priority candidates spanning preclinical, clinical, and commercial stages, including 11 novel drug candidates and 4 biosimilars. We focus on oncology and aging-related disease including immunology, bone disorders, ophthalmology, hematology, cardiovascular disease, etc. Of these, 4 products have been approved and commercialized, 1 candidate filed for pre-NDA meeting, 2 candidates are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and several provincial and municipal science and technological innovation projects.
Manufacturing Compliant with International Quality Standard We strive for excellence in quality and apply rigorous management systems to ensure the high quality of every batch of products for patients. The Taizhou pilot and commercial manufacturing base is compliant with international GMP standards, and has passed the EU QP Audit. To satisfy the expanding R&D pipeline and production demands, we have built a large-scale commercial manufacturing base in Shanghai and an ADC commercialized manufacturing base in Taizhou.
Milestone
2025

MAILISHENG Launched

First commercialized innovative drug of Mabwell First launched novel granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting fusion technology in China

License out

Agreement with Calico for 9MW3811 Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection Agreement with Kalexo Bio (NewCo) for 2MW7141
2024

MAIWEIJIAN Launched

First approved denosumab biosimilar (120mg) in China

Included in FTSE Global Equity Index Series

2023

License out

9MW3011 FDA/NMPA approval for IND; agreement with DISC MEDICINE. Inc with total milestone up to $412.5 million.

MAILISHU Launched

Second approved denosumab biosimilar worldwide
2022

Listing on the STAR Market

688062.SH

JUNMAIKANG Launched

Adalimumab biosimliar, first marketed product of Mabwell
2020

Series A financing

￥1.97 billion ($300M+)
2018

Industrial capability established

Taizhou manufacturing site in place Initiate Shanghai site construction Acquisition of Single B Cell Screening Platform Establish US innovation R&D site Establish ADC platform
2017

Mabwell founded

Integration of R&D resources

Establish high-throughput drug discovery platform Initiate construction of Taizhou manufacturing site
2016
LongRun Investment increased capital into Destiny Bio, improve the layout of antibody drug development.
2015
M&A of T-mab & Kohnoor
Awards
Innovation
2 National key research & development projects Multiple Biomedical Science and Technology Support Special Projects of Shanghai "Science & Technology Innovation Action Plan" High-tech Enterprises Shanghai Key Laboratory (Preparation) for Antibody-Drug Conjugates and Bispecific Antibodies Shanghai Innovative Technology Center for Antibody Drug Discovery and Industrialization
Achievements
2025 China's Top 101 Most Innovative Pharmaceutical Companies
2025
2025 China's Innovative Pharmaceutical Companies FNS101 · ADC Breakthrough Award
2025
Zhangjiang Innovative Pharmaceutical Enterprises Global Competitiveness TOP15
2025
Annual Industry List of New Power- Most Valuable Healthcare Companies for Investment
2024
2024 Yangtze River Delta Biomedical New Quality Leaders - Biomedical Innovation Leaders TOP20
2024
Top 10 Novel Drug R&D Teams of the Year
2024
Annual Pharmaceutical Innovation Pioneer Award
2024
Key listed unicorn enterprise
2024
Shanghai Top 100 Hardcore Technology Enterprises
2024
Human Resources Management Award
2024
Best Investment Value for Companies in China Pharmaceutical Industry
2023
Leading Hard Tech SSE Star Market Company
2023
1 2 3 Next
Contact
Add： BLDG 3, No. 576, Libing Rd., Pudong, Shanghai, P.R.C.
Tel： 021-58585793
Email： contact@welcomei.net
Fax： 021-58585793-6520
Compliance email： mw.compliance@welcomei.net
Shanghai
Beijing
Taizhou
Nanjing
San Diego
Datao Liu
Chairman of the Board, CEO

Recipient of Special Government Allowances of the State Council. The Leading Talent of Shanghai biomedicine industry. The Evaluation Expert of National Science & Technology Award. The Evaluation Expert of National Major New Drug Innovation Program. The Expert of Talents Evaluation of Ministry of Industry & Information Technology of P.R.C. The Special Fund Evaluation Expert of Shanghai Municipal Commission of Economy and Informatization. Member of Shanghai Industry-Medical Integration Strategy Advisory Committee. Vice Chairman of the council and member of the Expert Committee of the Society of Recombinant-Drugs of China Biochemical Pharmaceutical Industry Association. Secretary-General of Shanghai Industry Innovation Alliance of Biopharma (SIIAB).
Over 20 years of experience of R&D and industrialization of novel biologics. VP of the central research institute of Shanghai Pharma. GM of Shanghai Jiaolian Pharma. Deputy director, research institute of SINE.
Dr. Liu was responsible for about 40 major science projects including the 863 Program (National High-tech R&D Program), National Major Science and Technology Funding Projects, etc. Dr. Liu published over 20 academic papers with 5 patents granted.

Hai Wu
Board Member, President of R&D Dr. Wu obtained his Ph.D. in Genetics and Development from University of Texas Southwestern Medical Center and continued his postdoctoral training at Department of Pathology at Stanford University. As one of the founders and CSO of Junshi Biosciences and TopAlliance Biosciences Inc., Dr. Wu was responsible for early discovery of dozens of antibody biotherapeutics, and made contributions to the market approval of first China-made anti-PD-1 antibody. Prior to that, he served as R&D professional of novel biotherapeutics in Trellis Bioscience and Amgen. As senior scientist in Amgen, he was responsible for hybridoma mAb platform and participated in early-stage development of over 30 antibodies, bringing him rich experience in developing macromolecular drugs. 26 papers published and 9 patents granted.
Yinhan Guo
CDO Ph.D. in Pathology. R&D director of Tonghua Dongbao Pharmaceutical Co., Ltd. VP of Beijing CLKC Medicine Development Co., Ltd. CEO of Beijing Oriental TenGen Biomedical Co., Ltd. She has been working on R&D of novel drugs for over 20 years and has got about 20 IND applications and NDAs approved. Led and participated in more than 10 National Major New Drug Innovation Program and other national research projects. More than 20 papers published and 16 patents granted. High-Level Innovation Talent in Jilin Province. Evaluation expert of Beijing Science and Technology Award. Well-experienced in business administration, Project management, HR and legal affairs management. Certified patent agent and expertise in patent strategies.
Xin Du
CSO Ph.D. in biochemistry, Peking University. Post doctor in University of Texas Southwestern Medical Center, tutored by Nobel Laureate Dr. Bruce Beutler. Member of the International BioIron Society and American Society of Hematology. Principal scientist, COI Pharmaceutics. Assistant professor, UCSD. Assistant professor, The Scripps Research Institute. More than 20 years of experience in biomedical research and pharmaceutical R&D, covering a wide range of areas including hematology, iron metabolism, immunology, and cancer biology. More than 50 publications published with a cumulative impact factor of over 150.
Shuhai Wang
CMO, SVP Ph.D., Clinical Medicine, Fudan University. Professor of engineering. He worked as assistant to the president, director of clinical research center in Fosun Pharma Research Institute. Medical director, head of medical registration department and project management department in Sine Pharma (part of Shanghai Pharma Group). Over 15 years of experience in clinical research, scientific research management and team management. Expertise in GCP, drug registration regulations, clinical research strategies and plans, and overall managing experiment. Led and participated in over 10 clinical research projects, including National Major New Drug Innovation Programs and Shanghai Science and Technology Commission projects.
Huiguo Hu
Board Member, CCO, SVP, Secretary of the Board Master of Pharmaceutical Preparations, Shenyang Pharmaceutical University. He was GM of international business of 3S Pharmaceutical Group. GM of CN-GEN Mab. BD director & international business GM of CP GUOJIAN. Deputy director, director of international business, Sine Pharma (part of Shanghai Pharma Group). Rich experience in the fields of quality system, R&D management, BD, international RA and sales. Led ANDA projects, IND projects to US FDA and CTA projects to TGA. Principal head of National Major New Drug Innovation Program.
Jun Hua
CFO, VP IMBA from Tongji University and Certified AICPA, IPA, CIA, 6-sigma Black Belt etc. He has over 15 years of experience in financial management work in both multi-national and top domestic pharmaceutical companies. Such as GE, J&J, Roche, Henlius. Prior to joining Mabwell, Mr. Hua was GM of finance & procurement of Henlius. Head of China manufacturing finance, Head of APAC product development & medical finance, Head of commercial finance (channel & pricing) in Roche. Rich experience in different finance functions like accounting, internal control, FPA, M&A, strategic planning, product portfolio management, biz model, etc.
Han Li
VP About 30 years of industry experience and 5 years of clinician in Tianjin Second Hospital. Previously worked in GSK, Sanofi, Tide and Kelun. National sales director in Sanofi, managing a thrombosis team of over 1,000 people, with a business scale of more than 3.5 billion. VP and GM of two business divisions in Tide, managing a team of about 2,000 people with a business scale of over 5 billion. VP in Kelun, in charge of the marketing and medical dept., and responsible for the establishment of the training and the SFE dept.
Hua Ni
VP Director of the Manufacturing dept., Hefei Zhaofeng Pharmacy. Assistant to chief engineer, Shanghai Wanxing Pharmacy. Project manager, GM, chief engineer, and GM of engineering management dept., 3S GUOJIAN. Deputy GM, GM of CMAB. He has long been engaged in the research and management of biopharmaceutical industrialization technology, with rich experiences in biopharmaceutical technology and equipment, system integration, large-scale biopharmaceutical process development and industrialization.
Xi Chen
VP Master of biochemistry and molecular biology, Jilin University. MBA, Shanghai Jiao Tong University. Prior to joining Mabwell, she worked for multi-national companies like GE Healthcare, Roche Diagnostics, Illumina and Thermo Fisher, etc. Great China commercial head, Illumina. National sales leader, life sciences of GE Healthcare. China sales & BD director, Veritas Genetics. Solid management experience in marketing, business development, and sales management in life science and biopharma industry.
Xun Gui
Board Member, VP

Ph.D. in biochemistry and molecular biology, Xiamen University. Postdoctoral fellow at UTHealth®, in U.S. Young Industrial Talent in "Shanghai Industrial Elite" high-level talent training program, 2022. He has the field of tumor biotherapeutics in 10 years R&D experience. During the postdoctoral research, he focused on the discovery of innovative drugs related to oncology, autoimmune and infectious diseases and participated in the early development of multiple innovative global therapeutic antibody drugs targeting the LILRB family. First-in-Class myeloid immune checkpoint inhibitor targeting LILRB4 granted fast track status by FDA for relapsed or refractory acute myeloid Leukemia.
More than 20 academic papers in Nature, Nature Communications, Cancer Immunology Research and other international journals, with a cumulative impact factor of over 300 and total citations of over 1,200. Over 40 patent applications summitted and 8 international patents granted.

Shanshan Yu
VP Ph.D. in Biophysics from the University of Science and Technology of China, postdoctoral fellow in the Department of Pharmacology at the University of Minnesota. Shanshan Yu served at drug evaluation authorities and has extensive experience in evaluation of the pharmacological and safety aspects of various types of innovative products, such as antibody protein drugs, vaccines, and small molecules. She is a national GCP and GLP on-site inspector and has participated in multiple on-site inspections of national key innovative drugs, and developed a deep understanding of drug administration regulations and compliance supervision.
Weiyi Dong
VP Graduated from East China University of Science & Technology, major in chemical pharmacy. Previously Project head of CPIDI. Vice minister of investment planning for New Asiatic Pharmaceutical (part of Shanghai Pharma Group). Office supervisor, division head of investment plan, deputy general manager of investment development in strategy and investment committee of the board, Shanghai Pharmaceuticals Holding Co., Ltd. Deputy general manager of asset management, Deputy general manager of investment development, Shanghai pharmaceutical group Co., Ltd. Over 30 years of rich experience in biomedical industry construction and fixed assets management.